LumiraDx

Pharmaceutical giant Roche (SWX: ROG), based in Switzerland, has announced an agreement to acquire innovative diagnostic technology from UK-headquartered LumiraDx (OTCMKTS: LMDXF). The transaction, expected to close in mid-2024, involves an upfront payment of $295 million, complemented by up to an additional $55 million to support LumiraDx’s point-of-care business during…